Sector News

Turnstone Biologics nabs Bristol-Myers R&D exec as new research chief

November 15, 2017
Life sciences

Turnstone Biologics has poached Mike Burgess, MBChB, Ph.D., from Bristol-Myers Squibb to be its new head of R&D.

Burgess, who had been at BMS as its SVP, head of exploratory clinical and translational research since 2013, has jumped ship to the early-stage startup, which is focused on reviving the fortunes of research into oncolytic viruses and cancer vaccines.

He’s also had stints at Roche and Eli Lilly, but here joins a much smaller company where he will take complete charge of all of Turnstone’s R&D work across all stages.

The Canadian biotech uses rhabdovirus isolates to penetrate cancer cells and then destroy them, all the while whipping up a T-cell cancer vaccine attack on tumors. It’s starting off targeting non-small cell lung cancer, breast cancer, and esophageal cancers, testing its leading candidate on its own, and in combo with Merck’s Keytruda in non-small cell lung cancer.

Two other programs in the pipeline are tabbed for work next year in HPV-positive cancers and one more in prostate cancer. By the middle of next year, the company is set for four active clinical programs.

“Mike is one of the most respected research and development leaders in the pharmaceutical industry, and has successfully led the global development and registration of several anticancer medicines,” said Sammy Farah, Ph.D., president and CEO of Turnstone Biologics. “Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral immunotherapies and powerful immuno-oncology R&D capabilities.”

“Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer,” added Burgess. “Its unprecedented two-in-one therapeutic approach, which combines an oncolytic virus with an antigen-specific cancer vaccine, is a powerful platform for addressing the challenges of treating different solid tumors. I look forward to working closely with Turnstone’s experienced team and founders, who are driven by science and innovation, to bring these breakthrough medicines to patients.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach